Omnicell Q4 EPS Misses by $0.07, Revenue Up 2.3%, Raises FY26 Guidance
Omnicell’s Q4 EPS of $0.40 missed estimates by $0.07 while revenue rose 2.3% to $313.98 million. Management raised Q1 guidance to $0.26–$0.36 EPS and FY26 outlook to $1.65–$1.85 EPS, and Piper Sandler set a $49 price target.
1. Q4 Earnings and Stock Reaction
Omnicell reported Q4 EPS of $0.40, missing the consensus estimate of $0.47 by $0.07. The stock opened at $39.69 after closing at $46.69, last trading near $38.38 and experiencing a 16.3% intraday decline.
2. Revenue Growth and Profitability
Revenue for the quarter reached $313.98 million, slightly above the $313.36 million expectation and up 2.3% year-over-year. The company delivered a net margin of 1.69% and return on equity of 4.10%.
3. Guidance Raise and Price Target
Management set Q1 EPS guidance at $0.26 to $0.36 and full-year FY26 EPS at $1.65 to $1.85, reflecting improved outlook. Piper Sandler’s $49 price target implies roughly 25% upside from recent trading levels.